...
首页> 外文期刊>Prescrire international >New drugs and indications in 2013: little real progress but regulatory authorities take some positive steps
【24h】

New drugs and indications in 2013: little real progress but regulatory authorities take some positive steps

机译:2013年的新药和适应症:实际进展不大,但监管机构采取了一些积极措施

获取原文
获取原文并翻译 | 示例
           

摘要

In recent years, our annual reviews of new developments in the pharmaceutical market have repeatedly highlighted the paucity of therapeutic advances, the excessive number of dangerous new drugs and indications, and the disproportionately high prices of drugs used in oncology.Did things change in 2013? Among the 90 new drugs or indications Prescrire reviewed in 2013, more than half (48) did not provide an advantage over existing treatments and were rated "nothing new". This proportion has remained quite stable from one year to the next (see table page 109).Only 18 new drugs or indications represented a therapeutic advance, albeit often minimal. Six new drugs or indications were rated "offers an advantage" and 12 "possibly helpful" (a).
机译:近年来,我们对药品市场新发展的年度回顾一再强调了治疗进展的匮乏,危险新药和适应症的数量过多以及肿瘤学中使用的药品价格过高.2013年情况是否发生了变化?在2013年对Prescrire进行审查的90种新药或适应症中,超过一半(48)不能提供优于现有疗法的优势,被评为“没有什么新意”。从一年到下一年,这一比例一直保持稳定(请参阅第109页的表)。只有18种新药或适应症代表了治疗的进步,尽管通常很少。六种新药或适应症被评为“具有优势”,十二种“可能有帮助”(a)。

著录项

  • 来源
    《Prescrire international》 |2014年第148期|共3页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号